Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study

• Objective To evaluate the safety and effectiveness of tocilizumab and abatacept in systemic sclerosis Methods 20 patients with SSc with refractory polyarthritis and seven with refractory myopathy from Results After 5 months, tocilizumab induced a significant improvement in the 28-joint count Disease Conclusions In this observational study, tocilizumab and abatacept appeared to be safe and effective

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Reumatologi och inflammation (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Rheumatology and Autoimmunity (hsv//eng)

Nyckelord

eular scleroderma trials

research group database

dermal fibroblasts

interleukin-6

involvement

receptor

skin

collagen

disease

cells

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)